The Philippines is 1 of 22 countries considered to have a high burden of tuberculosis (TB) ([@R1]), including multidrug-resistant (MDR) TB (resistant to isoniazid and rifampin) ([@R1]). Compared with treatment for drug-susceptible TB, treatment for MDR TB is longer, more expensive, and less effective, and it causes more medication side effects ([@R2]--[@R5]). Resistance to anti-TB drugs has been detected in all regions of the Philippines; an estimated 8,500 MDR TB cases occurred in 2013 ([@R6]).

Programmatic Management of Drug-resistant Tuberculosis (PMDT) was jointly initiated in the Philippines in October 2000 by the private Makati Medical Center in Metro Manila and the Tropical Disease Foundation, Inc., in collaboration with the National TB Control Program and the local government unit, as the first directly observed therapy (DOTS)--plus pilot project for the management of MDR TB approved by the Green Light Committee ([@R7]). In 2003, a grant proposal from the Philippines for Round 2 of the Global Fund to Fight AIDS, Tuberculosis and Malaria included treatment for 500 patients with MDR TB (National Tuberculosis Control Program, the Philippines, 2013 Aug 25--Sep 6. Report of the Joint Program Review; 2013 Sep 30, unpub. data). This funding was approved and subsequently expanded to 2,500 MDR TB patients approved to receive treatment according to a Round 5 proposal. In 2010, a new coordination team for PMDT was established by the National TB Control Program/Department of Health; the Lung Center of the Philippines was the implementing arm for PMDT. As of September 2014, a total of 44 PMDT health facilities were located in 16 of 17 regions. The annual number of patients with drug-resistant TB who began receiving treatment under PMDT increased from 191 in the 2005 cohort to 2,056 in the 2012 cohort. Despite substantial progress made by PMDT in the Philippines, the proportion of patients for whom treatment was successful decreased from 73% in the 2005 cohort to 46% in the 2010 cohort, while the proportion of loss to follow-up increased from 13% to 38%, respectively ([@R8]). Even with recent efforts to improve retention of patients receiving treatment for TB (e.g., providing transportation allowance, financial incentives at treatment milestones, food baskets, and halfway houses for patients from remote areas), the proportion of patients lost to follow-up remains substantial.

An effective approach to reducing loss to follow-up during treatment for MDR TB is needed (National Tuberculosis Control Program, the Philippines, 2013 Aug 25--Sep 6. Report of the Joint Program Review; 2013 Sep 30, unpub. data), especially in light of data from a prospective multinational study demonstrating that among MDR TB patients lost to follow-up, almost a third had extensively drug-resistant or pre--extensively drug-resistant TB when treatment was started; drug resistance was acquired during treatment by an additional 12% ([@R9]*,*[@R10]). In addition, a third of those lost to follow-up remained culture-positive at last contact, enabling community transmission of strains with more extensive resistance ([@R10]). However, most studies of loss to follow-up were done retrospectively, through medical record reviews ([@R11]--[@R17]), and lacked a theoretical framework. Specific reasons why patients in the Philippines are lost to follow-up during MDR TB treatment are limited and based primarily on the views of healthcare providers. We aimed to determine which individual, diagnosis and treatment, interpersonal, healthcare setting, and social factors were significantly associated with patient loss to follow-up during MDR TB treatment in the Philippines.

Methods
=======

Study Design and Patient Population
-----------------------------------

We conducted a case--control study among adult patients ([\>]{.ul}18 years of age) with confirmed MDR or rifampin-resistant TB for whom treatment was initiated during July 1--December 31, 2012, at PMDT treatment facilities in the Philippines. We excluded from study inmates, children \<18 years of age, patients enrolled in pharmaceutical clinical trials, and patients who had a major psychiatric disorder or were physically incapacitated.

The study was approved by the institutional review board of the Tropical Disease Foundation, Inc., the Lung Center of the Philippines--Ethics Review Committee, and the Ethics Research Committee of the Philippine Tuberculosis Society, Inc. The US Centers for Disease Control and Prevention (CDC) determined that CDC staff involvement did not constitute engagement in human subject research and that submission for CDC institutional review board review was not required.

In the Philippines, the standardized treatment regimen for MDR TB is pyrazinamide, kanamycin, levofloxacin, prothionamide, and cycloserine; the intensive phase lasts [\>]{.ul}6 months and the continuation phase an additional [\>]{.ul}12 months. For this study, case-patients were defined as patients who were lost to follow-up from MDR TB treatment (i.e., patients whose treatment was interrupted for [\>]{.ul}2 consecutive months) ([@R18]). Those who later returned (after being considered lost to follow-up) at the time of interview were eligible for inclusion in the study as case-patients. Control-patients were defined as patients who had continued treatment for MDR TB for [\>]{.ul}12 months or who had a documented treatment outcome of cured, completed, or failed ([@R18]). Data collection and interviews were conducted from April 14 through July 31, 2014; thus, all control-patients were receiving MDR TB treatment for [\>]{.ul}15 months.

Case-patients were identified by review of MDR TB registers. The number of patients who were lost to follow-up per treatment facility was assessed; centers with [\>]{.ul}3 patients with drug-resistant TB who had been lost to follow-up by January 1, 2014, and who were not known to have died, were selected for logistical reasons. Field study staff attempted to find all eligible patients who were lost to follow-up and invite them to participate in the study. Two control-patients were randomly selected for each enrolled case-patient from the same PMDT treatment facilities at which treatment was initiated for case-patients. Of 986 eligible patients, a total of 273 were enrolled: 91 case-patients and 182 control-patients ([Figure 1](#F1){ref-type="fig"}).

![Selection of participants for study of loss to follow-up during treatment for multidrug resistant tuberculosis (MDR TB) in the Philippines, 2012--2014. \*Study exclusion criteria were incarceration, age \<18 years, enrollment in pharmaceutical clinical trials, and major psychiatric disorder or physical incapacitation. †Control-patients who did not give consent for the study were replaced by other randomly selected eligible patients.](15-1788-F1){#F1}

To characterize factors associated with loss to follow-up during MDR TB treatment, we followed a 5-level social ecologic model ([@R19]*,*[@R20]) that focuses on individual and environmental factors that affect health outcomes: 1) individual factors; 2) interpersonal factors; 3) healthcare setting factors, such as individual experiences with services and relationships within the setting; 4) diagnosis and treatment factors; and [@R5]) social factors ([Figure 2](#F2){ref-type="fig"}). To operationalize each category of factors and develop data collection forms, investigators reviewed TB literature and a 2013 Joint Program Review of the National Tuberculosis Control Program in the Philippines, which was led by the World Health Organization (WHO), and solicited input from experts within the country.

![Social ecologic model used to identify factors influencing loss to follow-up during treatment for multidrug resistant tuberculosis in the Philippines, 2012--2014. Boldface indicates data collected through patient interviews and medical record abstractions. DOTS, directly observed therapy.](15-1788-F2){#F2}

Data Collection
---------------

Clinical and laboratory data were abstracted from participants' medical records by using standard data collection forms. In-depth interviews with a series of closed- and open-ended questions were conducted to collect information about the following: demographics, social history, adverse drug reaction experiences, TB knowledge, perceived barriers to treatment completion, self-efficacy to adhere to treatment ([@R21]), values and expectancies associated with treatment; psychosocial factors (e.g., stigma, sources of emotional support, and family dynamics), financial support, perceptions of the healthcare setting, their diagnosis, their prescribed treatment, impressions of and feedback for the PMDT program regarding the current TB enabler package and patient-centered activities, and interventions under consideration. Cumulative scores were calculated from items focused on 1) patient perceptions of disease severity and TB knowledge; 2) expected outcomes, treatment self-efficacy; 3) patient-reported social support from family and friends; 4) trust in, rapport with, and support from health center staff; and 5) stigma ([Table 1](#T1){ref-type="table"}). Case-patients were asked to report their primary reason for stopping treatment. (Interview and scoring instruments are available from T.E.T.)

###### Calculation of summary scores in study of loss to follow-up during treatment for multidrug-resistant TB, the Philippines, 2012--2014\*

  Score type                                                                                                   Score calculation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Score interpretation
  ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  General TB knowledge, including understanding of severity of the disease and susceptibility to the disease   Participants were asked 15 questions that focused on 1) the severity of the TB problem in their community, 2) TB transmission and morbidity/mortality, and 3) TB treatment. Each item answered correctly was awarded 1 point. Incorrect answers or "Not sure" responses received 0 points. The summary score was extrapolated onto a scale of 100 and reported as a percentage by using the following formula: General TB knowledge score = (total points earned/15) × 100 (i.e., score is calculated on a scale of 0--100%).   A higher score may indicate greater TB knowledge and greater perceived severity and susceptibility to the disease.
  Expectations related to TB and its treatment                                                                 Participants were asked 5 interview questions aimed at determining their concerns for passing TB to loved ones, relapsing, and developing worsening drug resistance. Possible range of scores 5--15.                                                                                                                                                                                                                                                                                                                            A higher score may indicate greater concerns or an expectation that TB could cause problems in the future. In addition to factors such as knowledge, attitudes, and beliefs, expected outcomes can determine a person's actions. These expectations may be derived from 1) previous experiences, 2) observing or hearing about others in similar situations, 3) persuasive conversations, or 4) emotional or physical responses.
  Self-efficacy (or confidence) to adhere to treatment at the time treatment was about to begin                Eight interview questions were included in the self-efficacy questionnaire. "Very confident" = 3 points, "A little confident" = 2 points, "unsure" = 1 point, and "I knew I could not do this" = 0 points. The score for each item would be added together to calculate a cumulative self-efficacy score. Possible range of scores 0--24 points.                                                                                                                                                                                A higher score may indicate a high degree of self-reported self-efficacy for adhering to treatment regimen, coping with the treatment, and meeting with DOT staff when about to start treatment.
  Social support from family and friends                                                                       Score was based on responses to 3 interview questions with possible range of scores 3--15.                                                                                                                                                                                                                                                                                                                                                                                                                                      Lower scores may indicate less support.
  Trust in, rapport with, and support from physicians and nursing staff                                        An overall score was based on 22 items grouped together. Possible range of scores 22--110.                                                                                                                                                                                                                                                                                                                                                                                                                                      A higher score may indicate a greater level of trust, rapport, and perceived support. Items were separated by topic, and separate scores were also calculated for participants' 1) trust in, and rapport with physicians (13 questions); 2) trust in, and rapport with nurses (5 questions); and 3) perceived support from health center staff (4 questions).
  Patient self-stigmatization                                                                                  A cumulative score for stigma was based on 2 interview questions. Possible range of scores 1--10.                                                                                                                                                                                                                                                                                                                                                                                                                               A higher score may indicate less stigma.

\*DOTS, directly observed therapy; TB, tuberculosis.

Data Analysis
-------------

Data were entered in a Microsoft (Redmond, WA, USA) Access electronic database. Statistical analyses were performed by using SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA). Thematic qualitative analysis was conducted by using Microsoft Excel software.

We assessed associations between individual, interpersonal, healthcare setting, diagnosis and treatment, and social factor data and an outcome of lost to follow-up. For continuous variables, we compared means (SDs) or medians (percentiles) or both, depending on the underlying distributions. The proportions of patients with characteristics of interest were compared between case-patients and control-patients by χ^2^ or Fisher exact tests, as appropriate. We calculated odds ratios with corresponding 95% CIs. To identify independent factors associated with loss to follow-up, we performed multivariable logistic regression analyses. The initial multivariable model included covariates with epidemiologic, biological, or statistical associations with the dependent variable. We evaluated effect modification and confounding in the full model, and then we performed backward elimination to improve precision of the estimates ([@R22]). All tests were 2-sided, and a p value of [\<]{.ul}0.05 was considered statistically significant.

Results
=======

Mean ± SD age of the 273 study participants at start of MDR TB treatment was 39 ± 13 (median 40, range 16--68) years; 164 (60.1%) were male. An HIV test result was recorded for 56 (20.5%) of the 273 patients; 2 (3.5%) were HIV positive. All patients had pulmonary TB, and 35% had cavitary TB.

Most (70 \[77.8%\]) of the 90 case-patients for whom information on length of treatment was available were lost to follow-up during the intensive phase of treatment. Mean ± SD time receiving MDR TB treatment for case-patients was 7.8 ± 3.4 months (median 7 months; 25th percentile 4 months; 75th percentile 11 months) and for control-patients was 19.8 ± 1.7 months (median 20 months; 25th percentile 19 months; 75th percentile 21 months). Most (121 \[66.5%\]) of the 182 control-patients were still receiving treatment at the time of interview. Among 61 control-patients for whom treatment outcome was available, 35 (57.4%) experienced cure, 24 (39.3%) completed treatment, and 2 (3.3%) experienced treatment failure.

Univariate analysis indicated that individual factors significantly associated with loss to follow-up included older age (mean ± SD age 42 ± 13 years for case-patients vs. 38 ± 12 years for control-patients; p = 0.028); tobacco smoking (odds ratio \[OR\] 2.86, 95% CI 1.65--4.97); alcohol abuse (OR 1.93, 95% CI 1.09--3.40); and residence in an urban slum (OR 0.52, 95% CI 0.29--0.91) ([Table 2](#T2){ref-type="table"}). General knowledge of TB was significantly lower among case-patients than among control-patients; knowledge included understanding of the severity of and susceptibility to the disease (mean ± SD score 67.8 ± 16.3 vs. 74.3 ± 13.8, respectively; p\<0.001), but recall for self-confidence for adhering to treatment at the time of treatment start was significantly higher among case-patients (4.9 ± 5.3 vs. 2.44 ± 3.8, respectively, p\<0.001) ([@R20]).

###### Univariate analysis of Individual factors associated with loss to follow-up during treatment for multidrug-resistant TB, the Philippines, 2012--2014\*

  Factor                                                                                          Total†   Case-patients‡   Control-patients‡   Odds ratio (95% CI)   p value
  ----------------------------------------------------------------------------------------------- -------- ---------------- ------------------- --------------------- -------------
  Data from review of medical records                                                                                                                                 
  Demographics                                                                                                                                                        
  Sex                                                                                                                                                                 
  M                                                                                               164      60 (65.9)        104 (57.1)          1.45 (0.86--2.45)     0.16
  F                                                                                               109      31 (34.1)        78 (42.9)           1.00                  
  Age                                                                                             273      41.6 (13.2)§     38.0 (12.5)§        1.02 (1.00--1.04)¶    **0.028**
  Social history                                                                                                                                                      
  Tobacco smoking                                                                                                                                                     
  Current, past                                                                                   153      65 (73)          88 (48.6)           2.86 (1.65--4.97)     **\<0.001**
  Never                                                                                           117      24 (27)          93 (51.4)           1.00                  
  Alcohol abuse                                                                                                                                                       
  Current, past                                                                                   175      66 (75)          109 (60.9)          1.93 (1.09--3.4)      **0.02**
  Never                                                                                           92       22 (25)          70 (39.1)           1.00                  
  Drug abuse                                                                                                                                                          
  Current, past                                                                                   52       19 (22.4)        33 (18.6)           1.26 (0.67--2.37)     0.48
  Never                                                                                           210      66 (77.6)        144 (81.4)          1.00                  
  Clinical information                                                                                                                                                
  No. previous TB episodes                                                                        273      1.71 (0.90)§     1.62 (1.07)§        1.10 (0.86--1.40)¶    0.449
  BMI                                                                                                                                                                 
  \<18.5                                                                                          146      51 (56)          95 (52.2)           1.17 (0.7--1.94)      0.55
  [\>]{.ul}18.5                                                                                   127      40 (44)          87 (47.8)           1.00                  
  Cavitary TB disease                                                                                                                                                 
  Yes                                                                                             97       31 (44.3)        66 (41)             1.14 (0.65--2.02)     0.64
  No                                                                                              134      39 (55.7)        95 (59)             1.00                  
  Smear-positive at treatment start                                                                                                                                   
  Yes                                                                                             219      70 (82.4)        149 (85.1)          0.81 (0.41--1.63)     0.56
  No                                                                                              41       15 (17.6)        26 (14.9)           1.00                  
  Data from patient interviews                                                                                                                                        
  Total no. persons residing in household                                                         272      5.12 (2.79)§     5.53 (2.95)§        1.94 (0.63--5.99)¶    0.27
  Residence Comparison 1                                                                                                                                              
  Rural area                                                                                      40       15 (23.4)        25 (24.5)           0.94 (0.45--1.96)     0.88
  Urban slum                                                                                      126      49 (76.6)        77 (75.5)           1.00                  
  Residence Comparison 2                                                                                                                                              
  Urban area                                                                                      105      26 (34.7)        79 (50.6)           0.52 (0.29--0.91)     **0.02**
  Urban slum                                                                                      126      49 (65.3)        77 (49.4)           1.00                  
  Paid employment before starting treatment                                                                                                                           
  Yes                                                                                             126      49 (54.4)        77 (42.3)           1.63 (0.98--2.71)     0.06
  No                                                                                              146      41 (45.6)        105 (57.7)          1.00                  
  Employed before starting treatment but had to quit\#                                                                                                                
  Yes                                                                                             90       35 (79.5)        55 (83.3)           0.78 (0.29--2.07)     0.61
  No                                                                                              20       9 (20.5)         11 (16.7)           1.00                  
  Employed before starting treatment but fired/asked to take leave of absence\#                                                                                       
  Yes                                                                                             10       5 (35.7)         5 (31.3)            1.22 (0.27--5.59)     0.80\*\*
  No                                                                                              20       9 (64.3)         11 (68.8)           1.00                  
  Family sold belongings or household items (assets) to help pay expenses during TB treatment                                                                         
  Yes                                                                                             93       28 (31.8)        65 (35.7)           0.84 (0.49--1.44)     0.53
  No                                                                                              177      60 (68.2)        117 (64.3)          1.00                  
  Family borrowed money to cover costs due to TB illness                                                                                                              
  Yes                                                                                             181      60 (74.1)        121 (70.8)          1.18 (0.65--2.14)     0.58
  No                                                                                              71       21 (25.9)        50 (29.2)           1.00                  
  General TB knowledge††                                                                          272      67.81 (16.31)§   74.25 (13.78)§      0.97 (0.95--0.99)¶    **\<0.001**
  Expectations related to TB and TB treatment                                                     272      11.01 (1.87)§    10.76 (1.55)§       1.10 (0.94--1.28)¶    0.28
  Self-efficacy (or confidence) to adhere to treatment at the time treatment was about to begin   272      4.91 (5.28)§     2.44 (3.77)§        1.13 (1.06--1.19)¶    **\<0.001**

\*Boldface indicates significance. BMI, body mass index; TB, tuberculosis.  †Total reflects number of patients for whom data or responses for each respective category were available.  ‡No. (%) unless noted otherwise.  §Mean (SD).  ¶Odds ratio is per 1 unit increase. \#Of 126 patients who had paid employment before starting treatment, 90 reported that they subsequently "had to quit" and 10 reported that they had subsequently been "fired/asked to take leave of absence." \*\*Fisher exact test. ††Such as understanding of disease severity, susceptibility, scale 0%--100%).

Univariate analysis also indicated that the only interpersonal factor significantly associated with loss to follow-up was social support from family and friends. Scores were lower among case-patients than among control-patients (mean ± SD score 12.1 ± 3.4 vs. 12.9 ± 3.0, respectively, p = 0.047) ([Table 3](#T3){ref-type="table"}).

###### Univariate analysis of interpersonal factors associated with loss to follow-up during treatment for multidrug-resistant TB, the Philippines, 2012--2014\*

  Characteristic, from data from patient interviews   Total   Case-patients†   Control-patients†   Odds ratio (95% CI)   p value
  --------------------------------------------------- ------- ---------------- ------------------- --------------------- -----------
  Head of household‡                                                                                                     
  Yes                                                 91      37 (41.1)        54 (29.7)           1.65 (0.98--2.8)      0.06
  No                                                  181     53 (58.9)        128 (70.3)          1.00                  
  In charge of household budget                                                                                          
  Yes                                                 96      32 (35.6)        64 (35.2)           1.02 (0.6--1.72)      0.95
  No                                                  176     58 (64.4)        118 (64.8)          1.00                  
  Social support from family and friends              271     12.07 (3.35)§    12.87 (2.99)§       0.92 (0.85--1.00)¶    **0.047**

\*Boldface indicates significance. TB, tuberculosis. †No (%) unless noted otherwise.  ‡Provided more than half the cost of keeping up a home the year before becoming sick with TB.  §Mean (SD). ¶Odds ratio is per 1 unit increase.

Among healthcare setting factors, case-patients reported having received any type of assistance from the TB program significantly less often than control-patients: overall (OR 0.11, 95% CI 0.04--0.29), food (OR 0.46, 95% CI 0.27--0.79), free medications for treatment of adverse drug reactions (OR 0.28, 95% CI 0.16--0.48), or money for transportation (OR 0.19, 95% CI 0.1--0.37) **(**[Table 4](#T4){ref-type="table"}). Scores for trust in, rapport with, and support from physicians and nursing staff were significantly lower among case-patients than among control-patients (mean ± SD score 81.9 ± 15.6 vs. 90.7 ± 7.8, respectively; p\<0.001), as were scores for trust in and rapport with physicians (56.0 ± 11.5 vs. 62.2 ± 5.4, respectively; p\<0.001), trust in and rapport with nurses (21.8 ± 3.7 vs. 23.8 ± 2.4, respectively; p\<0.001), and information and support received from healthcare center staff (7.5 ± 1.7 vs. 8.4 ± 1.2, respectively; p\<0.001).

###### Univariate analysis of healthcare setting factors associated with loss to follow-up during treatment for multidrug-resistant TB, the Philippines, 2012--2014\*

  Characteristic, from data from patient interviews                                                 Total   Case-patients†   Control-patients†   Odds ratio (95% CI)   p value
  ------------------------------------------------------------------------------------------------- ------- ---------------- ------------------- --------------------- -------------
  Treatment center provided financial assistance or other items to facilitate treatment adherence                                                                      
  Yes                                                                                               245     69 (76.7)        176 (96.7)          0.11 (0.04--0.29)     **\<0.001**
  No                                                                                                27      21 (23.3)        6 (3.3)             1.00                  
  Types of assistance provided                                                                                                                                         
  Food products                                                                                                                                                        
  Yes                                                                                               114     27 (29.7)        87 (47.8)           0.46 (0.27--0.79)     **0.004**
  No                                                                                                159     64 (70.3)        95 (52.2)           1.00                  
  Housing assistance                                                                                                                                                   
  Yes                                                                                               15      6 (6.6)          9 (4.9)             1.36 (0.47--3.94)     0.57
  No                                                                                                258     85 (93.4)        173 (95.1)          1.00                  
  Free medications to treat side effects from anti-TB drugs                                                                                                            
  Yes                                                                                               196     49 (53.8)        147 (80.8)          0.28 (0.16--0.48)     **\<0.001**
  No                                                                                                77      42 (46.2)        35 (19.2)           1.00                  
  Money for transportation                                                                                                                                             
  Yes                                                                                               224     59 (64.8)        165 (90.7)          0.19 (0.1--0.37)      **\<0.001**
  No                                                                                                49      32 (35.2)        17 (9.3)            1.00                  
  Trust in, rapport with, and support from physicians and nursing staff                             273     81.88 (15.56)‡   90.73 (7.79)‡       0.93 (0.91--0.96)§    **\<0.001**
  Information and support from healthcare center staff                                              272     7.53 (1.68)‡     8.43 (1.22)‡        0.64 (0.52--0.78)§    **\<0.001**

\*Boldface indicates significance. TB, tuberculosis. †No (%) unless noted otherwise.  ‡Mean (SD).  §Odds ratio is per 1 point increase in cumulative score.

Among diagnosis and treatment factors, frequency of certain adverse drug reactions reported by patients did not differ significantly, except for less frequently reported diarrhea among case-patients (OR 0.49, 95% CI 0.29--0.85). However, scores for self-reported severity of adverse drug reactions were significantly higher among case-patients; reactions included vomiting (mean ± SD 5.23 ± 3.72 vs. 4.02 ± 3.46; p = 0.008), dizziness (5.48 ± 3.51 vs. 4.55 ± 3.14; p = 0.029), and fatigue or extreme tiredness (5.18 ± 3.56 vs. 4.14 ± 3.25; p = 0.017) ([Tables 5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}). Reported cost of travel to the treatment center during the intensive phase of treatment was significantly higher among case-patients than among control-patients (mean ± SD 98 ± 104 pesos vs. 71 ± 57 pesos, respectively, p = 0.035).

###### Univariate analysis of diagnosis and treatment factors associated with loss to follow-up during treatment for multidrug-resistant TB, the Philippines, 2012--2014\*

  Characteristic, data from patient interviews                                       Total   Case-patients†    Control-patients†   Odds ratio (95% CI)   p value
  ---------------------------------------------------------------------------------- ------- ----------------- ------------------- --------------------- -------------
  Side effects during MDR TB treatment‡                                                                                                                  
  Nausea                                                                                                                                                 
  Yes                                                                                230     74 (81.3)         156 (85.7)          0.73 (0.37--1.42)     0.35
  No                                                                                 43      17 (18.7)         26 (14.3)           1.00                  
  Vomiting                                                                                                                                               
  Yes                                                                                210     74 (81.3)         136 (74.7)          1.47 (0.79--2.75)     0.22
  No                                                                                 63      17 (18.7)         46 (25.3)           1.00                  
  Diarrhea                                                                                                                                               
  Yes                                                                                195     56 (61.5)         139 (76.4)          0.49 (0.29--0.85)     **0.01**
  No                                                                                 78      35 (38.5)         43 (23.6)           1.00                  
  Headache                                                                                                                                               
  Yes                                                                                212     68 (75.6)         144 (79.1)          0.82 (0.45--1.48)     0.50
  No                                                                                 60      22 (24.4)         38 (20.9)           1.00                  
  Sleep disturbances                                                                                                                                     
  Yes                                                                                231     75 (83.3)         156 (85.7)          0.83 (0.42--1.67)     0.61
  No                                                                                 41      15 (16.7)         26 (14.3)           1.00                  
  Tingling/pain in hands or feet                                                                                                                         
  Yes                                                                                187     55 (61.1)         132 (72.5)          0.6 (0.35--1.02)      0.06
  No                                                                                 85      35 (38.9)         50 (27.5)           1.00                  
  Hearing problems                                                                                                                                       
  Yes                                                                                202     68 (75.6)         134 (73.6)          1.11 (0.62--1.98)     0.73
  No                                                                                 70      22 (24.4)         48 (26.4)           1.00                  
  Dizziness                                                                                                                                              
  Yes                                                                                231     75 (83.3)         156 (85.7)          0.83 (0.42--1.67)     0.61
  No                                                                                 41      15 (16.7)         26 (14.3)           1.00                  
  Nervousness/anxiety                                                                                                                                    
  Yes                                                                                160     51 (56.7)         109 (59.9)          0.88 (0.53--1.46)     0.61
  No                                                                                 112     39 (43.3)         73 (40.1)           1.00                  
  Pain in joints                                                                                                                                         
  Yes                                                                                221     68 (75.6)         153 (84.1)          0.59 (0.31--1.09)     0.09
  No                                                                                 51      22 (24.4)         29 (15.9)           1.00                  
  Vision problems                                                                                                                                        
  Yes                                                                                155     53 (58.9)         102 (56)            1.12 (0.67--1.87)     0.66
  No                                                                                 117     37 (41.1)         80 (44)             1.00                  
  Fatigue/extreme tiredness                                                                                                                              
  Yes                                                                                208     70 (77.8)         138 (75.8)          1.12 (0.61--2.04)     0.72
  No                                                                                 64      20 (22.2)         44 (24.2)           1.00                  
  Participant travel expenses                                                                                                                            
  Cost to travel to treatment center, intensive phase of treatment                   239     97.58 (103.64)§   70.83 (57.24)§      1.00 (1.00--1.01¶     **0.035**
  Cost to travel to treatment center, continuation phase of treatment                138     67.93 (65.24)§    52.46 (39.37)§      1.01 (0.00--1.02)¶    0.383
  Source of funds to travel to/from treatment center, intensive phase of treatment                                                                       
  Own/personal money                                                                                                                                     
  Yes                                                                                203     68 (74.7)         135 (74.2)          1.03 (0.58--1.83)     0.92
  No                                                                                 70      23 (25.3)         47 (25.8)           1.00                  
  TB program funds                                                                                                                                       
  Yes                                                                                183     48 (52.7)         135 (74.2)          0.39 (0.23--0.66)     **\<0.001**
  No                                                                                 90      43 (47.3)         47 (25.8)           1.00                  
  Borrowed money                                                                                                                                         
  Yes                                                                                99      38 (41.8)         61 (33.5)           1.42 (0.85--2.39)     0.18
  No                                                                                 174     53 (58.2)         121 (66.5)          1.00                  

\*Boldface indicates significance. TB, tuberculosis. †No. (%) unless noted otherwise. ‡Participants were asked to rate severity of medication side effects on a scale of 1--10 (0 = absence of symptoms; 1 = very mild, 10 = extremely severe). §Mean (SD).  ¶Odds ratio is per 1 point increase in cost unit.

###### Rating of the severity of medication side effects experienced during treatment for multidrug-resistant TB, the Philippines, 2012--2014\*

  -------------------------------- ------- -------------------------------- ----------------------------------- ---------------------- -----------
  Side effect                      Total   Case-patients, mean (SD) score   Control-patients, mean (SD) score   Odds ratio (95% CI)†   p value
  Nausea                           273     5.05 (3.51)                      4.42 (3.18)                         1.06 (0.98--1.14)      0.136
  Vomiting                         273     5.23 (3.72)                      4.02 (3.46)                         1.10 (1.02--1.18)      **0.008**
  Diarrhea                         273     3.34 (3.41)                      3.74 (3.18)                         0.96 (0.89--1.04)      0.345
  Headache                         272     4.37 (3.36)                      4.20 (3.23)                         1.02 (0.94--1.10)      0.689
  Sleep disturbances               272     5.23 (3.59)                      5.31 (3.26)                         0.99 (0.92--1.07)      0.854
  Tingling/pain in hands or feet   272     3.58 (3.53)                      4.14 (3.56)                         0.96 (0.89--1.03)      0.218
  Hearing problems                 272     4.49 (3.47)                      4.13 (3.46)                         1.03 (0.96--1.11)      0.417
  Dizziness                        272     5.48 (3.51)                      4.55 (3.14)                         1.09 (1.01--1.18)      **0.029**
  Nervousness/anxiety              272     3.26 (3.34)                      3.01 (3.16)                         1.02 (0.95--1.11)      0.548
  Skin problems or rash            272     2.70 (3.26)                      2.69 (3.22)                         1.00 (0.93--1.08)      0.975
  Joint pain                       272     5.14 (3.57)                      5.49 (3.34)                         0.97 (0.90--1.04)      0.427
  Vision problems                  272     3.10 (3.07)                      2.80 (3.05)                         1.03 (0.95--1.12)      0.45
  Fatigue/extreme tiredness        272     5.18 (3.56)                      4.14 (3.25)                         1.10 (1.02--1.18)      **0.017**
  -------------------------------- ------- -------------------------------- ----------------------------------- ---------------------- -----------

\*Boldface indicates significance. TB, tuberculosis. †Odds ratio is per 1 point increase in severity rating score.

Univariate analysis indicated that social factors significantly associated with loss to follow-up were self-reported lack of time to go to the treatment facility (OR 2.23, 95% CI 1.1--4.54) and absence of someone to accompany the patient to the treatment facility during the intensive phase of treatment (OR 1.97, 95% CI 1.06--3.65). Scores reflecting patient self-stigmatization among case-patients and control-patients did not differ significantly (p = 0.10) ([Table 7](#T7){ref-type="table"}).

###### Univariate analysis of social factors associated with loss to follow-up during treatment for multidrug-resistant TB, the Philippines, 2012--2014\*

  Category                                                                                                                                          Total   Case-patients†   Control-patients†   Odds ratio (95% CI)   p value
  ------------------------------------------------------------------------------------------------------------------------------------------------- ------- ---------------- ------------------- --------------------- ----------
  Distance between participant\'s home and treatment center, intensive phase of treatment                                                                                                                              
  Comparison 1                                                                                                                                                                                                         
  0 to \<1 km                                                                                                                                       23      7 (23.3)         16 (31.4)           0.67 (0.24--1.87)     0.44
  1 to \<5 km (referent)                                                                                                                            58      23 (76.7)        35 (68.6)           1.00                  
  Comparison 2                                                                                                                                                                                                         
  5 to \<10 km                                                                                                                                      46      13 (36.1)        33 (48.5)           0.6 (0.26--1.37)      0.23
  1 to \<5 km (referent)                                                                                                                            58      23 (63.9)        35 (51.5)           1.00                  
  Comparison 3                                                                                                                                                                                                         
  [\>]{.ul}10 km                                                                                                                                    104     38 (62.3)        66 (65.3)           0.88 (0.45--1.7)      0.69
  1 to \<5 km (referent)                                                                                                                            58      23 (37.7)        35 (34.7)           1.00                  
  Comparison 4                                                                                                                                                                                                         
  Not sure/don\'t know                                                                                                                              42      10 (30.3)        32 (47.8)           0.48 (0.2--1.15)      0.10
  1 to \<5 km (referent)                                                                                                                            58      23 (69.7)        35 (52.2)           1.00                  
  Usual mode of transportation/transportation used to cover the greatest distance traveling to the treatment center, intensive phase of treatment                                                                      
  Walk                                                                                                                                                                                                                 
  Yes                                                                                                                                               37      19 (20.9)        18 (9.9)            2.4 (1.19--4.85)      **0.01**
  No                                                                                                                                                236     72 (79.1)        164 (90.1)          1.00                  
  Public transportation                                                                                                                                                                                                
  Yes                                                                                                                                               239     79 (86.8)        160 (87.9)          0.91 (0.43--1.92)     0.80
  No                                                                                                                                                34      12 (13.2)        22 (12.1)           1.00                  
  Personal vehicle                                                                                                                                                                                                     
  Yes                                                                                                                                               16      6 (6.6)          10 (5.5)            1.21 (0.43--3.45)     0.72
  No                                                                                                                                                257     85 (93.4)        172 (94.5)          1.00                  
  Major challenges when traveling to the treatment center, intensive phase of treatment                                                                                                                                
  The center was far away                                                                                                                                                                                              
  Yes                                                                                                                                               141     52 (57.8)        89 (48.9)           1.43 (0.86--2.38)     0.17
  No                                                                                                                                                131     38 (42.2)        93 (51.1)           1.00                  
  Did not always have money for transportation                                                                                                                                                                         
  Yes                                                                                                                                               193     71 (78)          122 (67.4)          1.72 (0.96--3.08)     0.07
  No                                                                                                                                                79      20 (22)          59 (32.6)           1.00                  
  Did not have the time to go for treatment                                                                                                                                                                            
  Yes                                                                                                                                               36      18 (19.8)        18 (9.9)            2.23 (1.1--4.54)      **0.02**
  No                                                                                                                                                236     73 (80.2)        163 (90.1)          1.00                  
  Going for treatment caused problems with work or school                                                                                                                                                              
  Yes                                                                                                                                               81      33 (36.3)        48 (26.5)           1.58 (0.92--2.71)     0.10
  No                                                                                                                                                191     58 (63.7)        133 (73.5)          1.00                  
  Did not have anyone to go with                                                                                                                                                                                       
  Yes                                                                                                                                               52      24 (26.4)        28 (15.4)           1.97 (1.06--3.65)     **0.03**
  No                                                                                                                                                221     67 (73.6)        154 (84.6)          1.00                  
  The center's hours were not convenient                                                                                                                                                                               
  Yes                                                                                                                                               23      11 (12.1)        12 (6.6)            1.95 (0.82--4.6)      0.12
  No                                                                                                                                                250     80 (87.9)        170 (93.4)          1.00                  
  Minutes to travel from home to treatment center, intensive phase of treatment                                                                     272     51.00 (43.56)‡   54.16 (45.03)‡      1.00 (0.99--1.00)§    0.583
  Minutes to travel from home to treatment center, continuation phase of treatment                                                                  198     22.25 (15.93)‡   31.07 (36.94)‡      0.99 (0.97--1.01)§    0.057
  Patient self-stigmatization                                                                                                                       272     6.20 (2.76)‡     5.66 (2.44)‡        1.09 (0.98--1.20)§    0.104

\*Boldface indicates significance. TB, tuberculosis. †No. (%) unless noted otherwise. ‡Mean (SD).  §Odds ratio is per 1 point increase in unit.

Independent factors positively associated with loss to follow-up were alcohol abuse (OR 2.84, 95% CI 1.39--5.80) and patient higher self-rating of vomiting severity (OR 1.10, 95% CI 1.01--1.21, per 1 point in severity rating score). Factors protective against loss to follow-up were receipt of any type of assistance from the TB program (OR 0.09, 95% CI 0.03--0.25); better general TB knowledge (OR 0.97, 95% CI 0.95--0.99, per 1 point in cumulative score); and higher levels of trust in, rapport with, and support from physicians and nursing staff (OR 0.93, 95% CI 0.90--0.96, per 1 point in cumulative score) ([Table 8](#T8){ref-type="table"}).

###### Multivariable analysis of factors associated with loss to follow-up during treatment for multidrug-resistant TB, the Philippines, 2012--2014\*

  Social ecologic model level, factor                        Odds ratio (95% CI)   p value
  ---------------------------------------------------------- --------------------- ---------
  Personal factors                                                                 
  Score TB knowledge                                         0.97 (0.95--0.99)†    0.003
  Alcohol abuse                                              2.84 (1.39--5.80)     0.004
  Healthcare setting factors                                                       
  Received assistance from TB program                        0.09 (0.03--0.25)     \<0.001
  Score trust/rapport with healthcare worker                 0.93 (0.90--0.96)†    \<0.001
  Diagnosis and treatment factors                                                  
  Self-rated severity of vomiting as adverse drug reaction   1.10 (1.01--1.21)‡    0.03

\*TB, tuberculosis.  †Odds ratio is per 1 point increase in cumulative score. ‡Odds ratio is per 1 point increase in severity rating score.

The primary reason for stopping treatment, most commonly reported by case-patients, was medication side effects or the fear of side effects, reported by 52 (58%) of 89 case-patients who responded to this question. The 2 other most commonly self-reported reasons for loss to follow-up were need to work and financial problems, reported by 25 (28%) of 89 patients, and lack of money for transportation to the treatment facility, reported by 18 (20%) of 89 patients.

Discussion
==========

This large study, guided by a 5-level theoretical social ecologic model, demonstrated that loss to follow-up from MDR TB treatment in the Philippines was independently associated with 2 individual factors (general TB knowledge and alcohol abuse), 2 healthcare setting factors (receiving any type of assistance from the TB program and levels of trust in, rapport with, and support from physicians, nursing staff and other healthcare workers in the treatment facilities), and 1 diagnosis and treatment factor (higher self-rated severity of vomiting as an adverse drug reaction). Multivariable analysis did not identify any interpersonal or social factors associated with loss to follow-up. The most commonly reported primary reason for loss to follow-up was medication side effects or fear of side effects.

This study demonstrated that general TB knowledge was significantly lower among case-patients than among control-patients. Although nonadherence to treatment rarely results from patient apathy, patients' lack of knowledge of their medical condition and its treatment is associated with poor health outcomes ([@R23]). For this reason, patient education is a valuable component of TB control. A recent systematic review and meta-analysis demonstrated that provision of patient education was a strategy associated with lower rates of loss to follow-up ([@R24]). Among TB patients, interventions to improve general TB knowledge are significantly associated with better outcomes ([@R25]). Knowledge of the bacterial causation of TB, mode of transmission, diagnostic testing, meaning of test results, rationale for prolonged treatment, and effect of treatment interruptions should be clearly explained to patients and their loved ones. It is also crucial to educate patients about expected adverse events before starting treatment. Patient education that addresses commonly held misperceptions about TB may also discourage patients from consulting traditional healers, thereby avoiding delayed diagnosis and treatment ([@R26]).

Alcohol abuse was recorded in medical records at a significantly higher frequency for case-patients than for control-patients. The association between alcohol abuse or alcohol use disorders and loss to follow-up during MDR TB treatment has been demonstrated in multiple studies ([@R13]--[@R15],[@R27]); 1 small randomized clinical trial demonstrated improved TB outcomes for patients in groups randomly assigned to receive naltrexone or behavioral counseling integrated into TB care ([@R28]). This finding, when combined with similar findings in other studies, calls for additional studies to assess the effect of using standard assessment tools to screen for alcohol dependence and of managing alcohol use as part of TB clinical services.

Receiving assistance from the TB program, including such measures as covering the cost of transportation, food, and housing, was associated with improved treatment adherence. However, if the process of applying for financial assistance is long and difficult and if this assistance is not given in a timely manner or regularly, patients may abandon their efforts to adhere to treatment. Decentralization of treatment (i.e., the transfer of care from a centralized MDR TB treatment center to a community DOTS facility) was protective; odds of being lost to follow-up decreased by 10 times ([@R12]). This finding suggests that the decentralization of care into multiple treatment facilities closer to patients' homes, which was used as part of the PMDT scale-up scheme in the Philippines, is a valid strategy for improving TB treatment patient retention. In addition to decentralization, the National TB Control Program began piloting the Community-Based PMDT Care Initiative in 2014 to provide a more accessible venue for management of MDR TB in the patient's home. The effectiveness of this initiative in improving treatment adherence should be rapidly evaluated, and the evaluation results should be used for future program planning. All modalities for addressing patient barriers should be considered. Adherence to MDR TB treatment might be improved by providing sufficient and timely financial assistance to patients (especially for transportation) by augmenting current enablers and providing livelihood programs during and after MDR TB treatment through strategic multisectoral partnership.

We found that levels of trust in, rapport with, and support from physicians, nursing staff, and other caregivers in the treatment facilities were significantly lower among patients lost to follow-up than among control-patients. A higher degree of trust, good rapport, and support from providers has been shown to be associated with patients' adherence to medical recommendations and with improvements to self-reported and objective measures of health ([@R29]*--*[@R31]). In a study by Holtz et al. in South Africa, the strongest individual risk factor for nonadherence to MDR TB treatment was having an unsatisfactory opinion about the attitude of the healthcare workers ([@R32]). Interventions focused on enhancing provider--patient mutual trust and respect are needed. Provider training with regard to active listening, health literacy, message-framing, motivational interviewing, communication skills for trust-building and sensitivity should be considered.

We found that patients' higher rating of the severity of their vomiting was independently associated with loss to follow-up. Moreover, the most commonly reported reason for stopping treatment (58%) was medication side effects. However, frequency of adverse drug reactions reported by patients in interviews did not differ significantly between case-patients and control-patients (except that diarrhea symptoms were reported significantly less often by case-patients than by control-patients). Still, case-patients reported significantly higher subjectively perceived severity of vomiting, dizziness, and fatigue as medication side effects. These symptoms affect quality of life and interfere with the capacity to work and the ability to engage in activities of daily living. A study of 583 MDR TB patients in the Philippines who had undergone treatment during 1999--2006 showed that taking \>5 drugs was significantly associated with loss to follow-up compared with taking 2--3 drugs ([@R12]). The authors interpreted the association between a higher drug burden and loss to follow-up as being related to more extensive drug resistance and competing risk for death among those patients. However, it also might be related to experiencing more side effects by the patients who received a higher number of toxic second-line drugs, which more likely led to stopping treatment, than by patients who received a lower number of drugs. Our study suggests that strict monitoring for, and appropriate treatment of, adverse drug reactions may help improve treatment adherence. Ancillary drugs must be included in procurement plans and made widely available at treatment facilities. Initial and refresher trainings for healthcare providers about management of adverse drug reactions and patient education about expected adverse drug reactions before treatment initiation may also help improve treatment adherence. Patients should understand the need for strict monitoring for adverse drug reactions and the availability of effective and free treatment for those reactions, especially reactions that are subjectively difficult for patients (e.g., nausea, vomiting, dizziness, and extreme fatigue).

Our study is subject to several limitations. As with any case--control study, it provides relatively weak empirical evidence. Because patient interviews were part of the protocol, deceased patients were excluded, which might have introduced survivor biases into our results. Almost a third of selected control-patients could not be located, which could bias the results in favor of selecting control-patients with a stronger relationship to the clinics. The retrospective nature of interviews is also subject to recall and exposure misclassification biases. Interview responses may reflect socially desirable answers rather than true thoughts and experiences. Some patients who were adherent to treatment at the time of the interview may be lost to follow-up at a later time (in this study, 66% of control-patients were still receiving treatment at the time of the interview); thus, outcome misclassification is possible. Identification of alcohol abuse was based on the records in medical charts without standardized assessment for each patient (such as the Alcohol Use Disorder Identification Test) ([@R33]). Previous studies have demonstrated that loss to follow-up from treatment was less in smaller cohorts ([@R24]) and was more with program scale-up ([@R34]). Thus, increased loss to follow-up may be related to healthcare setting structural factors such as insufficient number of facilities and providers or limited experience with management of MDR TB, but our study did not address those factors.

Despite these limitations, our study provides useful data. The interviews captured patients' perspectives and provided nuances that retrospective cohort studies lack ([@R11],[@R12],[@R15]--[@R17]). These data, along with medical record data, afford program leaders greater insight for improving services and designing patient-centered interventions to reduce loss to follow-up during MDR TB treatment in the Philippines. A revision of the PMDT strategy should address identified barriers to completing MDR TB treatment and implement actions that support patients' adherence to treatment.

###### Technical Appendix

Multivariable analysis used to assess factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012--2014.
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